Positron emission tomography and computer tomography (PET/CT) in prostate, bladder, and testicular cancers

Current Medicinal Chemistry

Volumn 17, Issue 23, 2010, Pages 2492-2502

  Zouhair, A ^a   Ozsahin, M ^a   Schaffer, M ^b   Albrecht, S ^a   Camus, F ^a   Jichlinski, P ^a   Mirimanoff, R O ^a   Bischof Delaloye, A ^a   Meuwly, J Y ^a   Prior, J O ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

bladder cancer; F 18 fluorodeoxyglucose; positron emission tomography; Prostate cancer; testicular cancer

Indexed keywords

ACETIC ACID C 11; CHOLINE C 11; CHOLINE F 18; FLUORINE 18; FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; FLUORODIHYDROTESTOSTERONE F 18; FUROSEMIDE; GALLIUM 68; METHIONINE C 11; OCTREOTIDE; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; BONE METASTASIS; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG EXCRETION; DRUG UPTAKE; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TESTIS CANCER; TREATMENT PLANNING; TREATMENT RESPONSE;

ANIMALS; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TESTICULAR NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 77955627956     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710791556014     Document Type: Article

References (86)

1. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Smigal, C.; Thun, M.J. Cancer statistics, 2006. CA Cancer J. Clin., 2006, 56, 106-130.
2. Pisansky, T.M. External-beam radiotherapy for localized prostate cancer. N. Engl. J. Med., 2006, 355, 1583-1591.
3. Tiguert, R.; Gheiler, E.L.; Tefilli, M.V.; Oskanian, P.; Banerjee, M.; Grignon, D.J.; Sakr, W.; Pontes, J.E.; Wood, D.P., Jr. Lymph node size does not correlate with the presence of prostate cancer metastasis. Urology, 1999, 53, 367-371.
4. Schoder, H.; Larson, S.M. Positron emission tomography for prostate, bladder, and renal cancer. Semin. Nucl. Med., 2004, 34, 274-292.
5. Ak, I.; Stokkel, M.P.; Pauwels, E.K. Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours. J. Cancer Res. Clin. Oncol., 2000, 126, 560-574.
6. Beyersdorff, D.; Winkel, A.; Hamm, B.; Lenk, S.; Loening, S.A.; Taupitz, M. MR imaging-guided prostate biopsy with a closed MR unit at 1.5 T: initial results. Radiology, 2005, 234, 576-581.
7. Weir, H.K.; Thun, M.J.; Hankey, B.F.; Ries, L.A.; Howe, H.L.; Wingo, P.A.; Jemal, A.; Ward, E.; Anderson, R.N.; Edwards, B.K. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J. Natl. Cancer Inst., 2003, 95, 1276-1299.
8. Bloch, B.N.; Furman-Haran, E.; Helbich, T.H.; Lenkinski, R.E.; Degani, H.; Kratzik, C.; Susani, M.; Haitel, A.; Jaromi, S.; Ngo, L.; Rofsky, N.M. Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging--initial results. Radiology, 2007, 245, 176-185.
9. Futterer, J.J. MR imaging in local staging of prostate cancer. Eur. J. Radiol., 2007, 63, 328-334.
10. Lichy, M.P.; Aschoff, P.; Plathow, C.; Stemmer, A.; Horger, W.; Mueller-Horvat, C.; Steidle, G.; Horger, M.; Schafer, J.; Eschmann, S.M.; Kiefer, B.; Claussen, C.D.; Pfannenberg, C.; Schlemmer, H.P. Tumor detection by diffusion-weighted MRI and ADCmapping- initial clinical experiences in comparison to PET-CT. Invest. Radiol., 2007, 42, 605-613.
11. Shukla-Dave, A.; Hricak, H.; Moskowitz, C.; Ishill, N.; Akin, O.; Kuroiwa, K.; Spector, J.; Kumar, M.; Reuter, V.E.; Koutcher, J.A.; Zakian, K.L. Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines. Radiology, 2007, 245, 499-506.
12. Durkan, G.C.; Greene, D.R. Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy? BJU Int., 1999, 83, 34-38.
13. DeGrado, T.R.; Baldwin, S.W.; Wang, S.; Orr, M.D.; Liao, R.P.; Friedman, H.S.; Reiman, R.; Price, D.T.; Coleman, R.E. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J. Nucl. Med., 2001, 42, 1805-1814.
14. 18fluorine-labeled deoxyglucose. J. Urol., 1996, 155, 994-998.
15. Liu, I.J.; Zafar, M.B.; Lai, Y.H.; Segall, G.M.; Terris, M.K. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology, 2001, 57, 108-111.
16. Partin, A.W.; Kattan, M.W.; Subong, E.N.; Walsh, P.C.; Wojno, K.J.; Oesterling, J.E.; Scardino, P.T.; Pearson, J.D. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multiinstitutional update. JAMA, 1997, 277, 1445-1451.
17. Yoshimoto, M.; Waki, A.; Yonekura, Y.; Sadato, N.; Murata, T.; Omata, N.; Takahashi, N.; Welch, M.J.; Fujibayashi, Y. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol, 2001, 28, 117-122.
18. Jana, S.; Blaufox, M.D. Nuclear medicine studies of the prostate, testes, and bladder. Semin. Nucl. Med., 2006, 36, 51-72.
19. Takahashi, N.; Inoue, T.; Lee, J.; Yamaguchi, T.; Shizukuishi, K. The Roles of PET and PET/CT in the Diagnosis and Management of Prostate Cancer. Oncology, 2008, 72, 226-233.
20. Igerc, I.; Kohlfurst, S.; Gallowitsch, H.J.; Matschnig, S.; Kresnik, E.; Gomez-Segovia, I.; Lind, P. The value of (18)F-Choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging, 2008, DOI 10.1007/s00259-00007-00686-00259.
21. Giovacchini, G.; Picchio, M.; Coradeschi, E.; Scattoni, V.; Bettinardi, V.; Cozzarini, C.; Freschi, M.; Fazio, F.; Messa, C. [(11)C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and antiandrogenic therapy. Eur. J. Nucl. Med. Mol. Imaging, 2008, DOI 10.1007/s00259-00008-00716-00252.
22. Li, X.; Liu, Q.; Wang, M.; Jin, X.; Liu, Q.; Yao, S.; Liu, S.; Li, J. C-11 choline PET/CT imaging for differentiating malignant from benign prostate lesions. Clin. Nucl. Med., 2008, 33, 671-676.
23. 11C-choline PET/CT using multimodality fusion techniques. J. Nucl. Med., 2009, 50, 1585-1593.
24. 11C-choline PET/CT. Radiology, 2007, 244, 797-806.
25. Barentsz, J.O.; Futterer, J.J.; Takahashi, S. Use of ultrasmall superparamagnetic iron oxide in lymph node MR imaging in prostate cancer patients. Eur. J. Radiol., 2007, 63, 369-372.
26. Heicappell, R.; Muller-Mattheis, V.; Reinhardt, M.; Vosberg, H.; Gerharz, C.D.; Muller-Gartner, H.; Ackermann, R. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose. Eur. Urol., 1999, 36, 582-587.
27. 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. Urol. Int., 2003, 70, 311-315.
28. Kotzerke, J.; Prang, J.; Neumaier, B.; Volkmer, B.; Guhlmann, A.; Kleinschmidt, K.; Hautmann, R.; Reske, S.N. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur. J. Nucl. Med., 2000, 27, 1415-1419.
29. 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res., 2000, 20, 2189-2192.
30. Morris, M.J.; Akhurst, T.; Osman, I.; Nunez, R.; Macapinlac, H.; Siedlecki, K.; Verbel, D.; Schwartz, L.; Larson, S.M.; Scher, H.I. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology, 2002, 59, 913-918.
31. Yeh, S.D.; Imbriaco, M.; Larson, S.M.; Garza, D.; Zhang, J.J.; Kalaigian, H.; Finn, R.D.; Reddy, D.; Horowitz, S.M.; Goldsmith, S.J.; Scher, H.I. Detection of bony metastases of androgenindependent prostate cancer by PET-FDG. Nucl. Med. Biol., 1996, 23, 693-697.
32. Price, D.T.; Coleman, R.E.; Liao, R.P.; Robertson, C.N.; Polascik, T.J.; DeGrado, T.R. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J. Urol., 2002, 168, 273-280.
33. 11C-choline PET. J. Nucl. Med., 2003, 44, 331-335.
34. Scher, B.; Seitz, M. PET/CT imaging of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 5-8.
35. Husarik, D.B.; Miralbell, R.; Dubs, M.; John, H.; Giger, O.T.; Gelet, A.; Cservenyak, T.; Hany, T.F. Evaluation of [(18)F]- choline PET/CT for staging and restaging of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 253-263.
36. Tuncel, M.; Souvatzoglou, M.; Herrmann, K.; Stollfuss, J.; Schuster, T.; Weirich, G.; Wester, H.J.; Schwaiger, M.; Krause, B.J. [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. Nucl. Med. Biol., 2008, 35, 689-695.
37. Pound, C.R.; Partin, A.W.; Eisenberger, M.A.; Chan, D.W.; Pearson, J.D.; Walsh, P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 1999, 281, 1591-1597.
38. Cox, J.D.; Gallagher, M.J.; Hammond, E.H.; Kaplan, R.S.; Schellhammer, P.F. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J. Clin. Oncol., 1999, 17, 1155.
39. Bott, S.R. Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic. Dis., 2004, 7, 211-216.
40. Haider, M.A.; Chung, P.; Sweet, J.; Toi, A.; Jhaveri, K.; Menard, C.; Warde, P.; Trachtenberg, J.; Lockwood, G.; Milosevic, M. Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Localization of Recurrent Prostate Cancer after External Beam Radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 2007.
41. Oyama, N.; Miller, T.R.; Dehdashti, F.; Siegel, B.A.; Fischer, K.C.; Michalski, J.M.; Kibel, A.S.; Andriole, G.L.; Picus, J.; Welch, M.J. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J. Nucl. Med., 2003, 44, 549-555.
42. Albrecht, S.; Buchegger, F.; Soloviev, D.; Zaidi, H.; Vees, H.; Khan, H.G.; Keller, A.; Bischof Delaloye, A.; Ratib, O.; Miralbell, R. (11)C-acetate PET in the early evaluation of prostate cancer recurrence. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, 185-196.
43. 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostatespecific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int., 2007, 99, 1415-1420.
44. de Jong, I.J.; Pruim, J.; Elsinga, P.H.; Vaalburg, W.; Mensink, H.J. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur. Urol., 2003, 44, 32-38; discussion 38-39.
45. Reske, S.N.; Blumstein, N.M.; Glatting, G. [(11)C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 9-17.
46. Scattoni, V.; Picchio, M.; Suardi, N.; Messa, C.; Freschi, M.; Roscigno, M.; Da Pozzo, L.; Bocciardi, A.; Rigatti, P.; Fazio, F. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur. Urol., 2007, 52, 423-429.
47. Krause, B.J.; Souvatzoglou, M.; Tuncel, M.; Herrmann, K.; Buck, A.K.; Praus, C.; Schuster, T.; Geinitz, H.; Treiber, U.; Schwaiger, M. The detection rate of [(11)C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 18-23.
48. Rinnab, L.; Simon, J.; Hautmann, R.E.; Cronauer, M.V.; Hohl, K.; Buck, A.K.; Reske, S.N.; Mottaghy, F.M. [(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World J. Urol., 2009, 27, 619-625.
49. 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol. Med., 2008, 113, 895-904.
50. Beheshti, M.; Vali, R.; Waldenberger, P.; Fitz, F.; Nader, M.; Hammer, J.; Loidl, W.; Pirich, C.; Fogelman, I.; Langsteger, W. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol. Imaging Biol., 2009, 11, 446-454.
51. 18F-fluoride PET/CT. J. Nucl. Med., 2006, 47, 287-297.
52. 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin. Nucl. Med., 2006, 36, 73-92.
53. 18F fluoride PET-CT: a comparative study. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 1766-1774.
54. Luboldt, W.; Zophel, K.; Wunderlich, G.; Abramyuk, A.; Luboldt, H.J.; Kotzerke, J. Visualization of Somatostatin Receptors in Prostate Cancer and its Bone Metastases with Ga-68-DOTATOC PET/CT. Mol. Imaging Biol., 2009.
55. Kwee, S.A.; Coel, M.N.; Ly, B.H.; Lim, J. (18)F-choline PET/CT imaging of RECIST measurable lesions in hormone refractory prostate cancer. Ann. Nucl. Med., 2009, 23, 541-548.
56. 18F-FDG in patients with progressive, metastatic prostate cancer. J. Nucl. Med., 2004, 45, 366-373.
57. Powles, T.; Murray, I.; Brock, C.; Oliver, T.; Avril, N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur. Urol., 2007, 51, 1511-1520; discussion 1520-1511.
58. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer. J. Nucl. Med., 2007, 48, 764-770.
59. 18F-FDG PET in abdominopelvic malignancies. J. Nucl. Med., 2006, 47, 1803-1807.
60. Kosuda, S.; Kison, P.V.; Greenough, R.; Grossman, H.B.; Wahl, R.L. Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur. J. Nucl. Med., 1997, 24, 615-620.
61. Bachor, R.; Kotzerke, J.; Reske, S.N.; Hautmann, R. [Lymph node staging of bladder neck carcinoma with positron emission tomography]. Urologe A, 1999, 38, 46-50.
62. Drieskens, O.; Oyen, R.; Van Poppel, H.; Vankan, Y.; Flamen, P.; Mortelmans, L. FDG-PET for preoperative staging of bladder cancer. Eur. J. Nucl. Med. Mol. Imaging, 2005, 32, 1412-1417.
63. Kibel, A.S.; Dehdashti, F.; Katz, M.D.; Klim, A.P.; Grubb, R.L.; Humphrey, P.A.; Siegel, C.; Cao, D.; Gao, F.; Siegel, B.A. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J. Clin. Oncol., 2009, 27, 4314-4320.
64. Swinnen, G.; Maes, A.; Pottel, H.; Vanneste, A.; Billiet, I.; Lesage, K.; Werbrouck, P. FDG-PET/CT for the Preoperative Lymph Node Staging of Invasive Bladder Cancer. Eur. Urol., 2009.
65. Ahlstrom, H.; Malmstrom, P.U.; Letocha, H.; Andersson, J.; Langstrom, B.; Nilsson, S. Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiol., 1996, 37, 180-185.
66. Albers, P.; Bender, H.; Yilmaz, H.; Schoeneich, G.; Biersack, H.J.; Mueller, S.C. Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. Urology, 1999, 53, 808-811.
67. Hain, S.F.; O'Doherty, M.J.; Timothy, A.R.; Leslie, M.D.; Partridge, S.E.; Huddart, R.A. Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur. J. Nucl. Med., 2000, 27, 590-594.
68. Spermon, J.R.; De Geus-Oei, L.F.; Kiemeney, L.A.; Witjes, J.A.; Oyen, W.J. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int., 2002, 89, 549-556.
69. De Santis, M.; Bokemeyer, C.; Becherer, A.; Stoiber, F.; Oechsle, K.; Kletter, K.; Dohmen, B.M.; Dittrich, C.; Pont, J. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J. Clin. Oncol., 2001, 19, 3740-3744.
70. De Santis, M.; Pont, J. The role of positron emission tomography in germ cell cancer. World J. Urol., 2004, 22, 41-46.
71. Oechsle, K.; Hartmann, M.; Brenner, W.; Venz, S.; Weissbach, L.; Franzius, C.; Kliesch, S.; Mueller, S.; Krege, S.; Heicappell, R.; Bares, R.; Bokemeyer, C.; de Wit, M. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J. Clin. Oncol., 2008, 26, 5930-5935.
72. Bokemeyer, C.; Kollmannsberger, C.; Oechsle, K.; Dohmen, B.M.; Pfannenberg, A.; Claussen, C.D.; Bares, R.; Kanz, L. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET. Br. J. Cancer, 2002, 86, 506-511.
73. Grosu, A.L.; Piert, M.; Weber, W.A.; Jeremic, B.; Picchio, M.; Schratzenstaller, U.; Zimmermann, F.B.; Schwaiger, M.; Molls, M. Positron emission tomography for radiation treatment planning. Strahlenther Onkol., 2005, 181, 483-499.
74. Paulsen, F.; Scheiderbauer, J.; Eschmann, S.M.; Brechtel, K.; Klein, M.; Pfannenberg, C.; Mondry, A.; Hehr, T.; Belka, C.; Bamberg, M. First experiences of radiation treatment planning with PET/CT. Strahlenther Onkol., 2006, 182, 369-375.
75. El Naqa, I.; Yang, D.; Apte, A.; Khullar, D.; Mutic, S.; Zheng, J.; Bradley, J.D.; Grigsby, P.; Deasy, J.O. Concurrent multimodality image segmentation by active contours for radiotherapy treatment planning. Med. Phys., 2007, 34, 4738-4749.
76. Drever, L.A.; Roa, W.; McEwan, A.; Robinson, D. Comparison of three image segmentation techniques for target volume delineation in positron emission tomography. J. Appl. Clin. Med. Phys., 2007, 8, 93-109.
77. Teh, B.S.; Paulino, A.C.; Lu, H.H.; Chiu, J.K.; Richardson, S.; Chiang, S.; Amato, R.; Butler, E.B.; Bloch, C. Versatility of the Novalis system to deliver image-guided stereotactic body radiation therapy (SBRT) for various anatomical sites. Technol. Cancer Res. Treat., 2007, 6, 347-354.
78. 18F-choline PET signal for target volume definition in radiation therapy of the prostate. Technol. Cancer Res. Treat., 2007, 6, 23-30.
79. [18F]Fluorocholine. http://www.ncbi.nlm.nih.gov/bookshelf/br. fcgi?book=micad&part=Choline18F (Last Accessed March 19, 2010),
80. [11C]Choline. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi? book=micad&part=Choline11C (Last Accessed March 19, 2010),
81. Leung, K. [11C]Acetate. http://www.ncbi.nlm.nih.gov/bookshelf/ br.fcgi?book=micad&part=Acetate11C (Last Accessed March 19, 2010),
82. [18F]Fluoro-2-deoxy-2-D-glucose. http://www.ncbi.nlm.nih.gov/ bookshelf/br.fcgi?book=micad&part=FDG (Last Accessed March 19, 2010),
83. Blau, M.; Ganatra, R.; Bender, M.A. 18 F-fluoride for bone imaging. Semin. Nucl. Med., 1972, 2, 31-37.
84. Reubi, J.C.; Schar, J.C.; Waser, B.; Wenger, S.; Heppeler, A.; Schmitt, J.S.; Macke, H.R. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med., 2000, 27, 273-282.
85. L-[methyl-11C]Methionine. http://www.ncbi.nlm.nih.gov/bookshelf/ br.fcgi?book=micad&part=MET11C (Last Accessed March 19, 2010),
86. Liu, A.; Dence, C.S.; Welch, M.J.; Katzenellenbogen, J.A. Fluorine-18-labeled androgens: radiochemical synthesis and tissue distribution studies on six fluorine-substituted androgens, potential imaging agents for prostatic cancer. J. Nucl. Med., 1992, 33, 724-734.